Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study

BACKGROUND: Advances in treatment have enabled patients with haemophilia A to live longer and therefore may be subjected to comorbidities associated with ageing, in addition to disease-associated morbidities. There have been few reports to date on efficacy and safety of treatment specifically in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Reding, Mark T., Pabinger, Ingrid, Holme, Pål Andrè, Maas Enriquez, Monika, Mancuso, Maria Elisa, Lalezari, Shadan, Miesbach, Wolfgang, Di Minno, Giovanni, Klamroth, Robert, Hermans, Cedric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126693/
https://www.ncbi.nlm.nih.gov/pubmed/37113811
http://dx.doi.org/10.1177/20406207231166779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126693/
https://www.ncbi.nlm.nih.gov/pubmed/37113811
http://dx.doi.org/10.1177/20406207231166779

Ejemplares similares